Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Inclusion Criteria: * Individuals with HCC BCLC stage 0 or A who received curative radiofrequency ablation or hepatic resection could be eligible. * Individuals who had single HCC (size \> 5.0 cm) received hepatic resection would be eligible * Individuals with prior history of HCC who had ever received curative ablation or hepatic resection without any recurrence for more than 2 years could be eligible if they had a new episode of recurrent HCC which could meet either of the former two criteria. * After 12+/-1 weeks of curative treatment, eligible patients who have no evidence of local residual or recurrent tumors according to the dynamic CT or MRI could be enrolled * The diagnosis of fresh HCC should be compatible with either pathological report or meet the criteria of AASLD guidelines Exclusion Criteria: * Undetermined nature of hepatic tumor * HCC with extrahepatic metastasis or major vascular invasion * With other malignant disease * Child Pugh score \>7 * Previous history of CAD event (angina, unstable angina, acute myocardial infarction) or ischemic stroke * Hyperlipidemia or other indication for statin (according to Taiwan NHI guideline) * Advanced CKD (eGFR\<30) or ESRD * Severe comorbidity with life expectancy \< 2 years * Allergy to statin